Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Shin Nippon Biomedical Laboratories (OTCPK:SBLOF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Shin Nippon Biomedical Laboratories's EV-to-EBIT for today is
Shin Nippon Biomedical Laboratories's current Enterprise Value is $430.1 Mil.
Shin Nippon Biomedical Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $42.1 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Shin Nippon Biomedical Laboratories's EV-to-EBITDA for today is:
Shin Nippon Biomedical Laboratories's current Enterprise Value is $430.1 Mil.
Shin Nippon Biomedical Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $64.3 Mil.
Shin Nippon Biomedical Laboratories's current Enterprise Value is $430.1 Mil.
Shin Nippon Biomedical Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $213.5 Mil.
Shin Nippon Biomedical Laboratories's current Enterprise Value is $430.1 Mil.
Shin Nippon Biomedical Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
Shin Nippon Biomedical Laboratories's current Enterprise Value is $430.1 Mil.
Shin Nippon Biomedical Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Enterprise Value Related Terms
Shin Nippon Biomedical Laboratories Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Enterprise Value Chart
SBLOF vs TMO, DHR, IDXX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Enterprise Value falls into.
Shin Nippon Biomedical Laboratories Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (SBLOF) has a Enterprise Value of $430.1 Mil as of Jun. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Shin Nippon Biomedical Laboratories and its competitors.
Is Shin Nippon Biomedical Laboratories' Enterprise Value too high?
Shin Nippon Biomedical Laboratories' current Enterprise Value is $430.1 Mil. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Enterprise Value compare to TMO and DHR?
Shin Nippon Biomedical Laboratories' Enterprise Value of $430.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Shin Nippon Biomedical Laboratories and its competitors. Shin Nippon Biomedical Laboratories's current Enterprise Value is $430.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Enterprise Value of $430.1 Mil. The stock's GF Value™ is $14.46, compared to a current price of $9.16 — trading 36.6% below its estimated fair value. The current Enterprise Value is $430.1 Mil. Shin Nippon Biomedical Laboratories' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Enterprise Value is $430.1 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 36.6% below its estimated GF Value™ of $14.46.
Key valuation signals for SBLOF:
Enterprise Value: $430.1 Mil
GF Value™: $14.46 vs. price of $9.16 (36.6% below fair value)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
77GF Score
Get the complete analysis for SBLOF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
